Clinical characteristics in Combined Pulmonary Fibrosis and Emphysema Syndrome vs Idiopathic Pulmonary Fibrosis patients

Similar documents
Defending the Rest Basics on Lung Cancer, Other Cancers and Asbestosis: Review of the B-Read and Pulmonary Function Testing

Position Statement from the Irish Thoracic Society on the treatment of Idiopathic Pulmonary Fibrosis

Staging of idiopathic pulmonary fibrosis: past, present and future

Cost-effectiveness of Pirfenidone (Esbriet ) for the treatment of Idiopathic Pulmonary Fibrosis.

Online supplements are not copyedited prior to posting.

Department of Surgery

Exploratory data: COPD and blood eosinophils. David Price: am

Co-morbiditeit associeert met respiratoire aandoeningen louter omwille van de leeftijd. COPD patiënten hebben veel meer kans op longkanker dan rokers

James F. Kravec, M.D., F.A.C.P

FIBROGENIC DUST EXPOSURE

National Learning Objectives for COPD Educators

Idiopathic Pulmonary Fibrosis (IPF) Research

Restrictive vs. Obstructive Disease (Dedicated to my good friend Joe Walsh)

The impact of emphysema in pulmonary fibrosis

PFF DISEASE EDUCATION WEBINAR SERIES. Welcome!

PULMONARY FUNCTION TESTS A Workshop on Simple Spirometry & Flow Volume Loops

Improvement in Dyspnea Implementing Pulmonary Rehabilitation in the Home

Cystic Lung Diseases. Melissa Price Gillian Lieberman, MD Advanced Radiology Clerkship Beth Israel Deaconess Medical Center November, 2008

Clinical Policy Title: Pulmonary Rehabilitation

Interstitial Lung Disease (Diffuse Parenchymal Lung Disease) Focusing on Idiopathic Pulmonary Fibrosis

Applicant Information Sheet for MASS 45 Adult Oxygen: Initial Application and 4 Month Review

Idiopathic Pulmonary Fibrosis

Interpretation of Pulmonary Function Tests

COPD and Asthma Differential Diagnosis

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Rehabilitation and Lung Cancer Resection. Roberto Benzo MD MS Mindful Breathing Laboratory Division of Pulmonary & CCM Mayo Clinic

Tests. Pulmonary Functions

CLINICAL PATHWAY. Acute Medicine. Chronic Obstructive Pulmonary Disease

Pulmonary Complications of Cancer Therapy. Marc B. Feinstein, MD Pulmonary Division Memorial Sloan-Kettering Cancer Center

EXPANDING THE EVIDENCE BASE IN OUTCOMES RESEARCH: USING LINKED ELECTRONIC MEDICAL RECORDS (EMR) AND CLAIMS DATA

A Multi-locus Genetic Risk Score for Abdominal Aortic Aneurysm

Documenting & Coding. Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Roofers: At Risk for Silicosis Arizona, Judith Eisenberg, M.D. May 17, 2006 AIHce Silica Roundtable

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Congenital Diaphragmatic Hernia. Manuel A. Molina, M.D. University Hospital at Brooklyn SUNY Downstate

The Global Alliance against Chronic Respiratory Diseases

Results of Surgery in a New Lung Institute in South Texas Focused on the Treatment of Lung Cancer

ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY

Pulmonary Disorders. Chronic Obstructive Pulmonary Disease (COPD) Chronic Obstructive Pulmonary Disease (COPD)

Abnormalities Consistent with Asbestos-Related Disease Among Long-Term Demolition Workers

Ventilation Perfusion Relationships

Your Go-to COPD Guide

SYNOPSIS. Risperidone: Clinical Study Report CR003274

Respiratory Conditions in Malaysian Asbestos Cement Workers

Best Practices in Managing Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pathway for Diagnosing COPD

J of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 3/ Issue 65/Nov 27, 2014 Page 13575

written by Harvard Medical School COPD It Can Take Your Breath Away

Severe asthma Definition, epidemiology and risk factors. Mina Gaga Athens Chest Hospital

When choosing a destination, it is important to keep the following in mind:

Pulmonary Rehabilitation COPD

Using Predictive Analytics to Reduce COPD Readmissions

Social inequalities impacts of care management and survival in patients with non-hodgkin lymphomas (ISO-LYMPH)

Leanne M Poulos Patricia K Correll Brett G Toelle Helen K Reddel Guy B Marks Woolcock Institute of Medical Research, University of Sydney, NSW

COPD It Can Take Your Breath Away

INTERSTITIAL LUNG DISEASE Paul F. Simonelli, MD, Ph.D.

COPD is the fourth most common cause of death. Gender Bias in the Diagnosis of COPD*

Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008

HEALTH CARE FOR EXPOSURE TO ASBESTOS The SafetyNet Centre for Occupational Health and Safety Research Memorial University

Pulmonary Rehabilitation: more than just an exercise prescription

Predictors of Physical Therapy Use in Patients with Rheumatoid Arthritis

30 DAY COPD READMISSIONS AND PULMONARY REHAB

Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD)

RESPIRATORY VENTILATION Page 1

Pulmonary Rehabilitation and Respiratory Therapy Services in the Physician Office Setting* Sam Birnbaum, BBA, CMPE; and Brian Carlin, MD, FCCP

Mortality Assessment Technology: A New Tool for Life Insurance Underwriting

Product Development News

nintedanib 100mg and 150mg capsules (Ofev ) SMC No. (1076/15) Boehringer Ingelheim

PAH in. Registry to Evaluate Early and Long-Term PAH Disease Management

ASK A DOC. Clinical Trial Update May 28, Welcome!

Written Example for Research Question: How is caffeine consumption associated with memory?

There may be up to 5 to 6 million cases of. Treatment Costs of Community- Acquired Pneumonia in an Employed Population*

Scottish Diabetes Survey Scottish Diabetes Survey Monitoring Group

CARE MANAGEMENT FOR LATE LIFE DEPRESSION IN URBAN CHINESE PRIMARY CARE CLINICS

PLAN OF ACTION FOR. Physician Name Signature License Date

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Review Article Imaging Diagnosis of Interstitial Pneumonia with Emphysema (Combined Pulmonary Fibrosis and Emphysema)

Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study

Adult Pulmonology. Glynna A. Ong-Cabrera MD, Percival A. Punzal MD, Teresita S. De Guia MD, Ma. Encarnita Blanco-Limpin MD

Acute Coronary Syndrome. What Every Healthcare Professional Needs To Know

MANCHESTER Lung Cancer Screening Program Dartmouth-Hitchcock Manchester 100 Hitchcock Way Manchester, NH (603)

MEDICARE BENEFITS SCHEDULE HEALTH INSURANCE COMMISSION DATA FOR CHRONIC CONDITIONS AND RISK FACTORS MARCH 2005

Combined smoke inhalation and body surface burns injury does not necessarily imply long-term respiratory health consequences

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis

Does smoking impact your mortality?

WA Asbestos Review Program

Corporate Medical Policy Genetic Testing for Alpha-1 Antitrypsin Deficiency

CT scans and IV contrast (radiographic iodinated contrast) utilization in adults

LUNG CANCER. How to spot the signs and symptoms and reduce your risk. cruk.org

Short-term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease

Standard of Care: Pulmonary Physical Therapy Management of the patient with pulmonary disease

Inhaled Corticosteroids and Diabetes Onset

Electronic Health Record (EHR) Data Analysis Capabilities

RR833. The joint effect of asbestos exposure and smoking on the risk of lung cancer mortality for asbestos workers ( )

Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD

NVVA symposium Gezondheidsbewaking en medische triage voor silicose in de bouwnijverheid

Coronary Heart Disease (CHD) Brief

49. INFANT MORTALITY RATE. Infant mortality rate is defined as the death of an infant before his or her first birthday.

Transcription:

Clinical characteristics in Combined Pulmonary Fibrosis and Emphysema Syndrome vs Idiopathic Pulmonary Fibrosis patients Jolanda Nikolla MD¹, Hasan Hafizi Prof ² ¹Pulmonologist, Hygeia Hospital Tirana, Albania ²Pulmonologist, Head of Pulmonology Department, UH Shefqet Ndroqi, Tirana, Albania Abstract: Aim: To identify differences between combined pulmonary fibrosis and emphysema syndrome (CPFE) and idiopathic pulmonary fibrosis (IPF) by a retrospective comparison of clinical data including clinical characteristics and baseline changes in pulmonary function. Methods: We studied demographic, clinical and physiologic features for two groups of patients, (total N=26) those with CPFE (7 males and 5 females) and them with IPF (5 males and 9 females). Results: The mean age was nearly the same.predominates males smokers in CPFE.IPF patients had lower FVC and MRC values and higher PO2 values. Conclusions: CPFE syndrome is a distinct entity. These patient are severely ill and should be differentiate from them with IPF. Keywords: Combined Pulmonary Fibrosis and Emphysema, Idiopathic Pulmonary Fibrosis Introduction: Combined pulmonary fibrosis and emphysema (CPFE) is characterized by upper lung predominant emphysema and lower lung predominant fibrosis. CPFE is predominant among male smokers and characterized by a relatively preserved lung volume and decreased diffusing capacity.this syndrome has been individualised in 2005 in smokers or exsmokers [1]. Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, and limited to the lungs. It is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis [2]. Patients with CPFE syndrome present with severe dyspnea and have a worse prognosis than patients with IPF [3]. Methods: Medical records and HRCT scans from January 2012 through April 2016 were reviewed retrospectively at our hospital. During this period we have had 26 patients with interstitial lung diseases (ILD). Among them, we identified CPFE patients through multidisciplinary discussion between our pulmonologists and radiologists. We diagnosed IPF patients with the HRCT scan imaging patterns according to the new ATS/ERS criteria [2,4].There were

12 patients with CPFE and 14 with IPF. Clinical and demographic data were gathered,such as age, gender, smoking history, dyspnea scale, clubbing, comorbidity, cardiac ultrasound and pulmonary function data. Some clinical characteristics and outcomes of patients with CPFE and IPF were compared. Statistical Methods : Clinical data are presented as means ± SDs or medians (range), depending on distribution.the significance and the relationship between factors were tested using EViews 7 program, a software that processes econometric various statistical difference for testing any hypothesis. Multivariable analysis will express the relationship between several variables with the simple or complex regression and the variance analysis. P-level < 0.05 was considered as statistically significant. RESULTS : The total number of the patients with ILD in the last four years in our hospital was 26 (N=26). 12 (46%) CPFE and 14 (54%) IPF. In both groups we found similiarities and features on demographic and pulmonary functional data (Tab 1). In CPFE predominates smokers or ex smokers and all of them are males 7 (66.66%).In IPF most of patients are females 9 (64.28%) and predominates patients nonsmokers. Mean age in both diseases is approximately the same (69.3 ± 7.1 years CPFE/ 68.3 ± 8.3 years in IPF). Mean BMI (body mass index) was relatively lower in CPFE than in IPF 27.34 ± 9.2/29.8 ± 3.6 respectively. In smokers and ex smokers patients UPY (Unit Pack Year) values was estimated and we found that patients with CPFE had higher UPY values (Graph 1,2). In both groups the most patients have lived in the urban areas in the major part of their life. Table 1 : Demographic data CPFE (n=12) IPF (n=14) Sex m/f % 7 (66.66%)/ 5(33.33%) 5 (35.72%)/ 9 (64.28%) Age, years, mean ± SD 69.3 ± 7.1 68.3 ± 8.3 BMI kg/m²,mean ± SD 27.34 ± 9.2 29.8 ± 3.6 Smoking status, n (%) n=7 n=5 never 5 (41.67%) 9 (64.28%) current 4 (33.33%) 3 (21.43%) ex-smoker 3 (25%) 2 (14.29%) UPY, mean ± SD 40.7 ± 15.6 31 ± 19.4 Urban / Rural areas 6 (50%)/ 6 (50%) 10 (71.42%)/4 (28.58%)

Graph 1: The distribution of UPY in CPFE Graph 2: The distribution of UPY in IPF 80 70 60 50 40 30 70 60 50 40 30 20 10 20 1 2 3 4 5 6 7 0 1 2 3 4 5 The mean time from symptoms to diagnosis was 2.08 ± 0.9 (years) for CPFE and 1.8 ± 0.8. The mean modified Medical Research Council (mmrc) dyspnea score was around 3 for CPFE and 2.8 for IPF. The predicted forced vital capacity (FVC) in percentage was lower in IPF but IT (Tiffneaou Index, the ratio of FEV1/ FVC in percentage), (FEV1,predicted forced expiratory volume in 1 second) was higher in CPFE. The mean partial pressures of oxygen (PaO2) in CPFE patients was 61.5 ± 9.4 mmhg and in the other group 64.5 ± 8.3 mmhg. Table 2 : Pulmonary function data CPFE (n=12) IPF (n=14) P - Value m MRC, mean ± SD 2.9 ±0.5 2.7 ± 0.5 0.0003 FVC, % mean ± SD 68.5 ± 11.4 61.7 ± 13.6 0.004 IT, %, mean ± SD 104.1 ± 10.3 99 ± 17.7 0.009 PO2, mean ± SD 61.5 ± 9.4 mmhg 64.5 ± 8.3 0.0006 Symptoms,mean ± SD 2.08 ± 0.9 (years) 1.8 ± 0.8 0.7840 Logistic regression analysis was performed for these five variables (tab 2). P value was calculated and exept for symptoms (p = 0.7) all the other variables (MRC,FVC,IT,PO2) had p < 0.05 that is statistically significant. The pulmonary functional variables make a difference in CPFE and IPF.

Graph 3. Compared FVC values 1 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0 FVC/mean FVC/median FVC/min FVC/max IPF CPFE Graph 4: Compared PO2 values 90 80 70 60 50 40 30 20 10 0 Po2/mes Po2/med Po2/min Po2/max CPFE IPF Discussion: Previous studies have also indicated that smoking is the most important risk factor especially in CPFE [5,6]. In our study predominates males patients in CPFE. In IPF were nonsmokers in most which means that probably the air pollution could possibly participate in the mechanism of IPF [7]. Dyspnea is

more severe in CPFE than in IPF. FVC values is lower in IPF patients and PO2 is lower in CPFE [8]. But our study has some limitations : the small number of the patients, it is a retrospective study, in one single center.we focused more on clinical findings but it has to be investigated more on this two entities. CONCLUSIONS: CPFE is a recently identified syndrome in smokers or ex-smokers characterized by dyspnea often severe, preserved lung volumes, severely impaired gas exchanges. Patients with these syndrome are severely ill and they have more needs for oxygen therapy. References [1]. Cottin V, Nunes H, Brillet P, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26(4):586e93. [2]. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An officia ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788e824 [3]. Fell CD. Idiopathic pulmonary fibrosis: phenotypes and comorbidities. Clin Chest Med 2012; 33:51 57. [4]. American Thoracic Society. American Thoracic Society/European Re- spiratory Society International Multidisciplinary Consensus Classifica- tion of the Idiopathic Interstitial Pneumonias.Am J Respir Crit Care Med 2002; 165: 277 304. [5]. Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010; 188(5): 365 373. [6]. Balbi B, Cottin V, Singh S, et al. Smoking-related lung diseases: a clinical perspective. Eur Respir J 2010; 35:231 233 [7]. Talmadge E King Jr, Annie Pardo, Moisés Selman. Idiopathic pulmonary fibrosis.lancet 2011; 378: 1949 61 [8]. Hamada K, Nagai S, Tanaka S, et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognos- ticator in patients with idiopathic pulmonary fibrosis. Chest 2007;131: 650 656.